In Brief: Cardiovascular & Renal Drugs Advisory Committee
Cardiovascular & Renal Drugs Advisory Committee: Feb. 27-28 meeting agenda is shuffled. Committee will consider Medco's Bidil for chronic congestive heart failure followed by SmithKline Beecham's Coreg for treatment of moderate chronic CHF on Feb. 27. On the morning of Feb. 28, Roche will present data on Posicor for treatment of hypertension and angina. In the afternoon, the committee will review Cor's Integrilin as an adjunct to aspirin or heparin in patients undergoing PTCA ("The Pink Sheet" Jan. 20, T&G-1)...
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth